natgillin/translations-raw huggingface dataset:
Cefovecin is a third generation cephalosporin with a broad-spectrum of activity against Gram-positive and Gram-negative bacteria. 
Cefovecin je cefalosporin tretje generacije s širokim spektrom delovanja proti grampozitivnim in gramnegativnim bakterijam.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2006 
Datum pridobitve dovoljenja za promet: 19/06/2006 Datum zadnjega podaljšanja dovoljenja za promet: 15/06/2011
A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site. 
Enkratno dajanje 22,5-kratnega priporočenega odmerka je povzročila prehodni edem in neugodje na mestu injiciranja.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na zunanji ovojnini.
If required, treatment may be repeated at 14 day intervals up to a further three times. 
Če je potrebno, zdravljenje ponovite do trikrat s 14-dnevnimi presledki.
Anaerobic bacteria such as Bacteroides spp. 
Anaerobne bakterije, kot so Bacteroides spp.
Cefovecin has unique pharmacokinetic properties with extremely long elimination half-lives in both dogs and cats. 
Cefovecin ima edinstvene farmakokinetične lastnosti z zelo dolgo razpolovno dobo izločitve pri psih in mačkah.
Not applicable. 
Ni smiselna.
Store in the original package in order to protect from light. 
Shranjujte v originalni ovojnini, za zaščito pred svetlobo.
Special precautions for use in animals: 
Posebni previdnostni ukrepi za uporabo pri živalih:
Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production) or from other mechanisms. 
Rezistenca na cefalosporine je rezultat encimske inaktivacije (proizvodnja β-laktamaze) ali drugih mehanizmov.
Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. 
Resne akutne preobčutljivostne reakcije lahko zahtevajo zdravljenje z epinefrinom in ostalimi nujnimi ukrepi, vključno s kisikom, intravenskimi tekočinami, intravenskim antihistaminikom, kortikosteroidi in inhalacijsko terapijo, kot je klinično indicirano.
Active substance: 
Pomožne snovi:
The antimicrobial activity of Convenia following a single injection lasts for up to 14 days. 
Protimikrobno delovanje zdravila Convenia po enkratnem injiciranju traja do 14 dni.
Following repeated administrations at the recommended dose, elevated concentrations of cefovecin were observed in plasma. 
Po ponovnem dajanju priporočenega odmerka, so bile v plazmi opažene povišane koncentracije cefovecina.
Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production), from reduced permeability by porin mutations or change in efflux, or by selection of low-affinity penicillin-binding proteins. 
Rezistenca na cefalosporine je rezultat encimske inaktivacije (proizvodnja β-laktamaze), zmanjšane propustnosti zaradi mutacij ali sprememb izliva proteina porin ali zaradi izbire za vezavo penicilinov manj privlačnih proteinov.
Pharmacotherapeutic group: Antibacterials for systemic use (cephalosporins). 
Farmakoterapevtska skupina: Antibiotiki za sistemsko uporabo (cefalosporini).
Cross resistance with other cephalosporins and other beta-lactam antibacterial agents can be observed. 
Navzkrižna rezistenca z ostalimi cefalosporini in beta laktamskimi antibiotiki je lahko prisotna.
INDICATION(S) For certain skin, soft tissue, urinary tract and severe periodontal infections. 
Določene infekcije kože, mehkega tkiva, urinarnega trakta in resne periodontalne infekcije.
It differs from other cephalosporins in that it is highly protein bound and has a long duration of activity. 
Od ostalih cefalosporinov se razlikuje po tem, da se močno veže na proteine in ima podaljšano delovanje.
Dog Cat Pasteurella multocida Dog Cat 
Pasteurella multocida pes maček
QUANTITY OF THE ACTIVE SUBSTANCE(S) Each vial contains 852 mg cefovecin. 
Vsaka viala vsebuje 852 mg cefovecina.
The powder is off-white to yellow and the diluent (solvent) is a clear, colourless liquid. 
Prašek je sivo bele do rumene barve, vehikel je jasna, brezbarvna tekočina.
Reconstitution yields either 4 ml or 10 ml of solution for injection respectively. 
Po rekonstituciji dobite 4 ml oziroma 10 ml raztopine za injiciranje.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
EU/2/06/059/002 (5 ml) 
EU/2/06/059/001(23 ml) EU/2/06/059/002 (5 ml)
If an allergic reaction occurs, no further administrations of cefovecin should be administered and appropriate therapy for beta-lactam hypersensitivity should be instituted. 
Če se pojavi alergična reakcija, je potrebno prekiniti z dajanjem cefovecina ter začeti s primerno terapijo proti beta-laktamski preobčutljivosti.
Pack size: 1 vial of powder and 1 vial of diluent. 
Pakiranje: 1 viala praška in 1 viala vehikla.
ADVICE ON CORRECT ADMINISTRATION 
NASVET O PRAVILNI UPORABI ZDRAVILA
Concurrent use of other substances that have a high degree of protein binding (e.g. furosemide, ketoconazole, or non-steroidal anti-inflammatory drugs (NSAIDs)) may compete with cefovecin binding and thus may cause adverse effects. 
Sočasna uporaba zdravil, ki imajo visoko stopnjo vezave na proteine (npr. furosemid, ketokonazol ali nesteroidna protivnetna zdravila (NSAID)), lahko konkurira z vezavo cefovecina in tako povzroči neželene učinke.
Citric acid 
Citronska kislina
Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other drugs. 
Posebna previdnost je potrebna pri pacientih, pri katerih se je že pokazala preobčutljivostna reakcija na cefovecin, cefalosporine, peniciline ali ostala zdravila.
It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins. 
Priporočljivo je, da cefalosporine tretje generacije uporabite za zdravljenje kliničnih stanj, ki so slabo reagirala ali se pričakuje, da bodo slabo reagirala, na ostale antibiotike ali prvo generacijo cefalosporinov.
Shelf-life after reconstitution according to directions: 28 days. 
Rok uporabnosti po rekonstituciji v skladu z navodili: 28 dni
After reconstitution, use within 28 days. 
Rekonstituirano zdravilo uporabite v 28 dneh.
Pseudomonas spp., Enterococcus spp., and Bordetella bronchiseptica isolates are inherently resistant to cefovecin. 
Pseudomonas spp., Enterococcus spp., in Bordetella bronchiseptica izolati so že naravno rezistentni na cefovecin.
Special precautions for use in animals 
Posebni previdnostni ukrepi za uporabo pri živalih
On very rare occasions gastrointestinal signs, including emesis and/or diarrhoea, have been observed. 
V zelo redkih primerih so bili opaženi znaki gastrointestinalnih motenj s slabostjo in/ali drisko.
PACKAGE SIZE 10 ml (after reconstitution) 4 ml (after reconstitution) 
10 ml (po rekonstituciji) 4 ml (po rekonstituciji)
CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV
Peak concentrations in tissue cage fluid of 31.9 μg/ml were measured 2 days after administration. 
Vrh koncentracije 31,9 µg/ml v tekočini tkivne kletke je bil izmerjen 2 dni po dajanju.
In-vitro activity against these pathogens as well as against other skin and urinary tract pathogens collected during a European (Denmark, France, Germany, Italy and United Kingdom) MIC survey (1999 - 2000) 
In-vitro učinkovitost proti tem patogenom kot tudi proti ostalim patogenom kože in urinarnega trakta, ki so bili zbrani med evropskim (Danska, Francija, Nemčija, Italija in Velika Britanija) MIC pregledom (1999 - 2000) ter med evropskimi (Francija, Nemčija, Španija in Velika Britanija) kliničnimi študijami glede učinkovitosti in varnosti (2001 - 2003), je predstavljena v spodnji preglednici.
In very rare cases neurological signs and injection site reactions have been reported after the use of the product. 
V zelo redkih primerih so po uporabi zdravila poročali o nevroloških simptomih in reakcijah na mestu injiciranja.
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. 
Penicilini in cefalosporini lahko povzročijo preobčutljivost (alergijo) po injiciranju, inhalaciji, zaužitju ali kontaktu s kožo.
The percentage of cefovecin resistant isolates in E. coli, Prevotella oralis, Bacteroides spp. 
Deleži na cefovecin rezistentnih izolatov pri E. coli, Prevotella oralis, Bacteroides spp.
Powder and solvent for solution for injection. 
Prašek in vehikel za raztopino za injiciranje.
and Prevotella spp. 
in Prevotella spp.
Cat 
maček
Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention. 
Pri pojavu resnejših kliničnih znakov, kot so otekanje obraza, ustnic, vek ali težav pri dihanju, je potrebno takoj poiskati zdravniško pomoč.
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only. 
BESEDILO “SAMO ZA ŽIVALI” Samo za živali.
Dog Cat 
pes maček
Porphyromonas gingivalis and Prevotella intermedia collected from canine periodontal disease were also shown to be susceptible. 
Porphyromonas gingivalis in Prevotela intermedia, ki so bile izolirane pri periodontalnem obolenju psov, so prav tako občutljive.
To ensure a correct dosage, body weight should be determined as accurately as possible to avoid underdosing. 
Da bi zagotovili pravilen odmerek ter se izognili premajhnemu odmerjanju, čimbolj natančno določite težo živali.
At fourteen days after administration, urine concentrations were 2.9 μg/ml. 
Štirinajst dni po dajanju je bila koncentracija v urinu 2,9 µg/ml.
MARKETING AUTHORISATION NUMBER(S) EU/2/06/059/001 (23 ml vial) EU/2/06/059/002 (5 ml vial) 
EU/2/06/059/001 (23 ml viala) EU/2/06/059/002 (5 ml viala)
Skin and soft tissue infections in dogs: 
Infekcije kože in mehkega tkiva pri psih:
Coagulase positive Staphylococcus spp.3, 4 
Koagulaza pozitivni Staphylococcus spp.3, 4
The product is available in a single pack of either 5 ml or 23 ml, composed of a vial containing the freezedried powder, and a second vial containing the diluent. 
Zdravilo je na voljo v posameznem pakiranju z eno 5- ali 23-mililitrsko vialo, ki vsebuje liofiliziran prašek, in eno vialo z vehiklom.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Penicilini in cefalosporini lahko povzročijo preobčutljivost (alergijo) po injiciranju, inhalaciji, zaužitju ali kontaktu s kožo.
MANUFACTURER'S BATCH NUMBER Lot: {number} 
IZDELOVALČEVA ŠTEVILKA SERIJE
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo:
For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp. 
Za zdravljenje infekcije urinarnega trakta povezane z Escherichia coli in/ali Proteus spp.
Dog 29 ≤0.008 
maček 24 ≤0,06
However, if stored as recommended, potency is not affected. 
Če zdravilo hranite v skladu z navodili, je učinkovitost nespremenjena.
13 mg/ml benzyl alcohol 
13 mg/ml benzilalkohola
Each 5 ml vial of lyophilised powder contains: 
Ena 5 ml viala z liofiliziranim praškom vsebuje:
852 mg cefovecin (as sodium salt) 
852 mg cefovecina (v obliki natrijeve soli)
Skin and soft tissue abscesses and wounds in cats: 
Abscesi in rane kože in mehkega tkiva pri mačkah:
For the treatment of urinary tract infections associated with Escherichia coli. 
Za zdravljenje infekcije urinarnega trakta povezane z Escherichia coli.
In cats, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 2 hours was 141 µg/ml and bioavailability approximately 99 %. 
Po enkratnem subkutanem dajanju odmerka 8 mg/kg telesne teže pri mačkah, se je cefovecin hitro in obsežno resorbiral; vrh plazemske koncentracije po 2-h urah je bil 141 µg/ml in biorazpoložljivost približno 99 %.
To reconstitute, withdraw the required volume of the supplied diluent from its vial (for 23 ml vial containing 852 mg of lyophilised powder reconstitute using 10 ml of diluent, or for 5 ml vial containing 340 mg of lyophilised powder reconstitute using 4 ml of diluent) and add to the vial containing the lyophilised powder. 
Za rekonstitucijo prenesite zahtevano količino vehikla iz viale z vehiklom (za 23 ml vialo, ki vsebuje 852 mg liofiliziranega praška, uporabite 10 ml vehikla, za 5 ml vialo, ki vsebuje 340 mg liofiliziranega praška, uporabite 4 ml vehikla) v vialo z liofiliziranim praškom.
When applying a proposed microbiological breakpoint of I ≤ 4 µg/ml, cefovecin resistance in S. pseudintermedius and beta-haemolytic Streptococci isolates was less than 0.02 % and 3.4 % in Prevotella intermedia isolates. 
Ob dajanju predlaganega mikrobiološkega odmerka I ≤ 4 µg/ml, je bila rezistenca na cefovecin Pri S. pseudintermedius in beta-hemolitičnih Streptococci izolatih je bila rezistenca manj kot 0,02 % ter 3,4 % pri Prevotella intermedia izolatih.. Deleži na cefovecin rezistentnih izolatov pri E. coli, Prevotella oralis, Bacteroides spp.
When applying a proposed microbiological breakpoint of S ≤ 2 µg/ml, no resistance to cefovecin was detected in Pasteurella multocida, Fusobacterium spp. 
Ob dajanju predlaganega mikrobiološkega odmerka S ≤ 2 µg/ml, pri Pasteurella multocida, Fusobacterium spp.
Fourteen days after administration, the mean cefovecin concentration in plasma was 5.6 μg/ml. 
Štirinajst dni po dajanju je bila povprečna koncentracija cefovecina v plazmi 5,6 µg/ml.
BATCH NUMBER Lot: {number} 
Lot: {številka}
STATEMENT OF ACTIVE SUBSTANCES The reconstituted solution for injection contains: 80.0 mg/ml cefovecin (as sodium salt) 
Raztopina za injiciranje po rekonstituciji vsebuje: 80,0 mg/ml cefovecina (v obliki natrijeve soli)
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats. 
Ponavljajoče se dajanje (8 odmeranje) petkratnega odmerka s 14-dnevnim intervalom so mlade mačke dobro prenašale.
In dogs, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 6 hours was 120 µg/ml and bioavailability approximately 99 %. 
Po enkratnem subkutanem dajanju odmerka 8 mg/kg telesne teže pri psih, se je cefovecin hitro in obsežno resorbiral; vrh plazemske koncentracije po 6-ih urah je bil 120 µg/ml in biorazpoložljivost približno 99 %.
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young dogs. 
Ponavljajoče se dajanje (8 odmerjanj) petkratnega odmerka s 14-dnevnim intervalom so mladi psi dobro prenašali.
and Proteus spp. 
in Proteus spp.
The percentage of cefovecin resistant isolates in coagulase negative Staphylococci spp. 
Delež na cefovecin rezistentnih izolatov pri koagulaza negativnih Staphylococci spp.
In addition, cefovecin exhibits in-vitro activity against Escherichia coli which is associated with canine and feline urinary tract infections. 
Poleg tega cefovecin kaže in-vitro učinkovitost proti Escherichia coli, ki je povezana z infekcijo urinarnega trakta pri psih in mačkah.
The percentage of cefovecin resistant isolates in coagulase negative Staphylococcus spp. 
Delež na cefovecin rezistentnih izolatov pri koagulaza negativnih Staphylococcus spp.
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, β haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida. 
Za zdravljenje infekcije kože in mehkega tkiva vključno s piodermo, ranami in abscesi, povezanimi z okužbo s Staphylococcus pseudintermedius, β-hemolitičnimi Streptococci, Escherichia coli in/ali Pasteurella multocida.
13 mg/ml benzyl alcohol 4.45 ml water for injections 
13 mg/ml benzilalkohola 4,45 ml vode za injekcije
Type I glass vial of either 10 ml or 19 ml with chlorobutyl rubber stopper sealed with an aluminium flipoff seal. 
10- ali 19-mililitrska viala, steklo tipa I, s klorobutilnim gumijastim zamaškom zapečatenim z aluminijastim pokrovom.
At ten and fourteen days after administration, urine concentrations were 1.3 µg/ml and 0.7 µg/ml, respectively. 
Koncentracija v urinu je bila 1,3 µg/ml 10 dni po dajanju in 0,7 µg/ml 14 dni po dajanju.
1 Lowest concentration, which completely inhibits visible growth of at least 50 % of isolates 2 Lowest concentration, which completely inhibits visible growth of at least 90 % of isolates 3 Some of these pathogens (e.g. S. aureus) exhibited natural in vitro resistance to cefovecin 4 The clinical significance of these in vitro data has not been demonstrated. 
2 Najnižja koncentracija, ki povsem inhibira vidno rast najmanj 90 % izolatov
NAME OF THE VETERINARY MEDICINAL PRODUCT Diluent for Convenia 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight). 
Enkratno subkutano dajanje 8 mg/kg telesne teže (1 ml na 10 kg telesne teže).
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
Escherichia coli 
Escherichia coli pes maček
Staphylococcus pseudintermedius 
Staphylococcus psudintermedius pes maček β hemolitični
Active substance: 340 mg cefovecin (as sodium salt) 
340 mg cefovecina (v obliki natrijeve soli)
Each 19 ml vial of diluent contains: 
Ena 19 ml viala z vehiklom vsebuje:
Dog4 Cat4 
pes maček4
Powder: Type I glass vial of either 5 ml or 23 ml with butyl rubber stopper sealed with an aluminium flip-off seal. 
5- ali 23-mililitrska viala, steklo tipa I, z butilnim gumijastim zamaškom zapečatenim z aluminijastim pokrovom.
Slight and transient injection site swellings were observed after the first and second administration. 
Po prvem in drugem dajanju so opazili prehodno rahlo oteklino na mestu injiciranja.
Fourteen days after administration the mean cefovecin concentration in plasma was 18 µg/ml. 
Štirinajst dni po dajanju je bila povprečna koncentracija v plazmi 18 µg/ml.
A single subcutaneous injection. 
Enkratno subkutano dajanje.
Each 10 ml vial of diluent contains: 
Ena 10 ml viala z vehiklom vsebuje:
Coagulase negative Staphylococcus spp.4 
Koagulaza negativni Staphylococcus spp.
Urinary tract infections in dogs and cats: A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight). 
Infekcije urinarnega trakta pri psih in mačkah: Enkratno subkutano dajanje 8 mg/kg telesne teže (1 ml na 10 kg telesne teže).
19.17 mg methyl parahydroxybenzoate (E218) 2.13 mg propyl parahydroxybenzoate (E216) 
19,17 mg metilparahidroksibenzoata (E218) 2,13 mg propilparahidroksibenzoata (E216)
To reconstitute, withdraw of the required volume of the supplied diluent from its vial (for 23 ml vial containing 852 mg of lyophilised powder reconstitute using 10 ml of diluent, or for 5 ml vial containing 340 mg of lyophilised powder reconstitute using 4 ml of diluent) and add to the vial containing the lyophilised powder. 
852 mg liofiliziranega praška, uporabite 10 ml vehikla, za 5 ml vialo, ki vsebuje 340 mg liofiliziranega praška, uporabite 4 ml vehikla) v vialo z liofiliziranim praškom.
SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use. 
s.c. Pred uporabo preberite navodilo za uporabo.
Dosing Table 
Tabela za odmerjanje
7.67 mg methyl parahydroxybenzoate (E218) 0.85 mg propyl parahydroxybenzoate (E216) 
7,67 mg metilparahidroksibenzoata (E218) 0,85 mg propilparahidroksibenzoata (E216)
or Porphyromonas spp. 
in Porphyromonas spp.
6.5 Nature and composition of immediate packaging 
6.5 Vrsta ovojnine in vsebina Prašek:
Cefovecin exhibits in-vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections. 
Cefovecin kaže in-vitro učinkovitost proti Staphylococcus pseudintermedius in Pasteurella multocida,
QUANTITY OF THE ACTIVE SUBSTANCE(S) 340 mg cefovecin 
340 mg cefovecina
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years. 
Rok uporabnosti zdravila v pakiranju za prodajo: 3 leta Rok uporabnosti po rekonstituciji v skladu z navodili: 28 dni
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Dogs and cats: 8 mg cefovecin/kg body weight (1 ml/10 kg body weight). 
Psi in mačke: 8 mg cefovecina/ kg telesne teže (1 ml/10 kg telesne teže).
Urinary tract infections in dogs and cats: A single subcutaneous injection. 
Infekcije urinarnega trakta pri psih in mačkah:
Severe infections of the gingival and periodontal tissues in dogs: A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight). 
Infekcije kože in mehkega tkiva pri psih: Enkratno subkutano dajanje 8 mg/kg telesne teže (1 ml na 10 kg telesne teže).
QUANTITY OF OTHER SUBSTANCES 13 mg/ml benzyl alcohol in water for injections. 
13 mg/ml benzilalkohola v vodi za injekcije
Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Benzyl alcohol 
Metilparahidroksibenzoat (E218) Propilparahidroksibenzoat (E216)
ADVERSE REACTIONS 
POSEBNA OPOZORILA
C. STATEMENT OF THE MRLs Not applicable. 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription. 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
For the treatment of skin and soft tissue abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis, β haemolytic Streptococci and/or Staphylococcus pseudintermedius. 
Fusobacterium spp., Bacteroides spp., Prevotella oralis, β-hemolitičnimi Streptococci in/ali s Staphylococcus pseudintermedius.
NAME OF THE VETERINARY MEDICINAL PRODUCT Convenia 80 mg/ml powder and solvent for solution for injection for dogs and cats cefovecin 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Convenia 80 mg/ml prašek in vehikel za raztopino za injiciranje za pse in mačke cefovecin
SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children. 
Zdravilo shranjujte nedosegljivo otrokom.
NAME OF THE VETERINARY MEDICINAL PRODUCT Convenia 80 mg/ml powder for solution for injection for dogs and cats 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Convenia 80 mg/ml prašek za raztopino za injiciranje za pse in mačke
PARTICULARS TO APPEAR ON THE OUTER PACKAGE OUTER CARTON (CONTAINING LYOPHILISED POWDER VIAL AND DILUENT VIAL) 23 ml Vial - 5 ml Vial 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA (VSEBUJE VIALO Z LIOFILIZIRANIM PRAŠKOM IN VIALO Z VEHIKLOM)
1.8 mg/ml methyl parahydroxybenzoate (E218) 0.2 mg/ml propyl parahydroxybenzoate (E216) 12.3 mg/ml benzyl alcohol 
Po rekonstituciji, skladni z navodili, raztopina za injiciranje vsebuje 80,0 mg/ml cefovecina (v obliki natrijeve soli) 1,8 mg/ml metilparahidroksibenzoat a(E218) 0,2 mg/ml propilparahidroksibenzoat a(E216) 12,3 mg/ml benzilalkohola
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL (5 ml LYOPHILISED POWDER VIAL) 
NALEPKA (5 ML VIALA Z LIOFILIZIRANIM PRAŠKOM)
Animal Weight (Dogs and Cats) Volume to be Administered 2.5 kg 
Teža živali (psi in mačke)
STATEMENT OF THE MRLs 
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
QUALITATIVE AND QUANTITATIVE COMPOSITION Each 23 ml vial of lyophilised powder contains: Active substance: 
Ena 23 ml viala z liofiliziranim praškom vsebuje: